ANI Pharmaceuticals reported its Q2 2026 results highlighting ongoing commercialization progress following its 2024 Alimera Sciences acquisition, which expanded its Rare Disease segment with ophthalmology products ILUVIEN and YUTIQ. The company’s multi-segment business includes Generics, Brands, and Rare Disease portfolios, supported by three manufacturing facilities producing a wide range of dosage forms. Regulatory expansions, particularly the FDA’s broadened indication for ILUVIEN, along with strategic product focus shifts within ophthalmology, underpin growth drivers. However, supply chain dependence on single-source active pharmaceutical ingredient (API) suppliers and outsourcing partners remains a material operational risk. ANI maintains robust liquidity and a conservative balance sheet as it balances expansion investments with regulatory and competitive pressures.